From GlobeNewswire: 2025-02-11 07:30:00

Medicus Pharma Ltd. (NASDAQ: MDCX) has entered into a Standby Equity Purchase Agreement with YA II PN, LTD, allowing the Company to sell up to US$15,000,000 of common shares to the Investor over 36 months. The Investor’s purchase is subject to conditions, including an SEC registration filing. Shares will be priced at 97% of the Market Price during a specified period. The Company also announced the voluntary delisting of its Shares from the TSX Venture Exchange, pending approval. The Shares will continue to be listed on Nasdaq. Shareholders in Canada can trade Shares through Nasdaq.

Medicus Pharma Ltd. focuses on accelerating clinical development programs for innovative therapeutics. Its subsidiary, SkinJect Inc., is developing a non-invasive treatment for basal cell skin cancer. The Company completed a phase 1 safety study in 2021 and submitted a phase 2 clinical protocol to the FDA in 2024. Patient recruitment for the study is ongoing in nine U.S. sites. Forward-looking statements in the news release caution investors about potential risks and uncertainties. Additional information can be found in the Company’s filings with the SEC and SEDAR+.



Read more at GlobeNewswire: Medicus Pharma Ltd. Enters into Standby Equity Purchase